Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 88INDUSTRY 4NIH 3NETWORK 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1

Conditions

Sarcoma, Clear Cell 1Neoplasms 1Klatskin Tumor 1Gastrointestinal Neoplasms 1Cholangiocarcinoma 1Arthritis, Rheumatoid 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Hydroxychloroquine × Clear all
NCT05221320 2025-09-25

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

BioMed Valley Discoveries, Inc

Phase 2 Terminated
47 enrolled 18 charts
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

NCT03377179 2025-07-23

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

RedHill Biopharma Limited

Phase 2 Completed
65 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT04593758 2023-05-24

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Cornerstone Pharmaceuticals

Phase 1/2 Completed
16 enrolled
Sarcoma

Sarcoma, Clear Cell

NCT03449758 2022-04-28

SariPRO

Sanofi

Phase 4 Completed
84 enrolled 36 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡